Bavar­i­an Nordic inks an­oth­er ma­jor vac­cine con­tract with Cana­da

As mon­key­pox cas­es con­tin­ue to af­fect na­tions in North Amer­i­ca and across the globe, Cana­da is look­ing to step up its pre­ven­tion ef­forts via a boost­ed con­tract with Bavar­i­an Nordic.

The Pub­lic Health Agency of Cana­da (PHAC) an­nounced on Tues­day that it has changed its con­tract with the Dan­ish drug­mak­er. The agree­ment will see Bavar­i­an Nordic de­liv­er its Jyn­neos vac­cine, al­so known as Im­va­mune, to the PHAC at a val­ue of $234 mil­lion, in ad­di­tion to $180 mil­lion in con­tract op­tions span­ning 10 years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER